Zydus Cadila, an Ahmedabad-based innovative, global pharmaceutical company, has received the final approval from the US Food and Drug Administration (FDA ) to market pyridostigmine bromide tablets USP, 60 mg.
According to IMS, the estimated sales of pyridostigmine bromide tablets USP which is used in the treatment of various neurological disorders is USD 27.9 million in 2015.
The group now has 100 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.